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Abstract
Background: Macrophage activation syndrome (MAS) is a severe complication of rheumatic disease in childhood,
particularly in systemic Juvenile Idiopathic Arthritis (sJIA). It is characterize by an uncontrolled activation and
proliferation of T lymphocytes and macrophages.
Main content: MAS is currently classified among the secondary or acquired forms of haemophagocytic
lymphohistiocytosis (sHLH). The reason is that MAS shares clinical and laboratory features with primary genetic
HLH (pHLH). In this context is conceivable that some of the pathogenic mechanisms of pHLH may be involved
in other forms of HLH. Heterozygosity for mutations of genes involved in pHLH may lead to a cytotoxic defect
and to a development of clinical overt disease. But other different contributors might be involved to the
development of MAS such as infections or underlying inflammation. In MAS, the inflammatory status of the
patient is a major contributor of the disease. Indeed, the majority of the MAS episodes occurs during active
disease phases or at disease onset. In addition, recent evidence in animals and humans suggest that genetics may also
play a major role in contributing to hyperinflammation and particularly to macrophages hyper-responses.
Conclusions: We hypothesize that HLH may be one unique clinical syndrome, to whose generation different
mechanisms may contribute, and maintained by one final effector mechanism.
Keywords: Macrophage activation syndrome, Haemophagocytic lymphohistiocytosis, IL-6, IL-18, IFNγ, Inflammasome,
Natural killer
Background
The term Macrophage Activation Syndrome (MAS)
identifies a potentially fatal complication of rheumatic
diseases. It occurs usually in the context of systemic
Juvenile Idiopathic Arthritis (sJIA), but it may occur also,
albeit more rarely, in systemic Lupus Erythematosus and
Kawasaki disease.
MAS is typically characterized by high fever, lym-
phoadenopathy, hepatosplenomegaly variably associated
with hemorrhages, signs of liver, central nervous system
and kidney involvement, and may lead to multiple
organ failure. Laboratory abnormalities include de-
crease in white blood cells, platelet and hemoglobin,
hypertransaminasemia, marked increase in ferritin, and
evidence for intravascular coagulation activation.
MAS clinical and laboratory features
Minoia et al. collected in a multinational multicentre
study 362 cases of patients with diagnosis of MAS, in the
context of sJIA, established by the treating physicians. All
patients had fever, a relevant percentage of them (58%)
had splenomegaly and lymphadenopathy (51%). Sur-
prisingly, 35% of them had symptoms suggestive of
CNS involvement, 16% had pericarditis, which is con-
sistent with systemic JIA, and 20% had clinical evidence
of consumption coagulopathy. See Appendix 1: Case 1
for laboratory abnormalities in sJIA and MAS. In the
large multinational study, the great majority of the
patients had high ferritin. All the patients had liver
involvement and, in the great majority of them, transami-
nases (94%) and LDH (94%) were abnormal. Anaemia
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(92%) was very frequent; however, thrombocytopenia
(70.3%) and neutropenia (54.5%) were not as frequent as
in primary HLH (pHLH). Triglycerides (93%) were
elevated in the majority of patients; evidence of intravas-
cular coagulation, as demonstrated by elevated d-dimer,
was present in the great majority of the patients (97%).
Fibrinogen was not below the normal limit in a significant
portion of patients (48.6%), as expected in highly inflam-
matory disease where fibrinogen behaves as a positive
acute phase protein [1].
Classification
In general, MAS is classified among the secondary forms
of haemophagocytic lymphohistiocytosis (sHLH), as a
sHLH occurring in the context of a rheumatic disease
(Table 1), the reason being that HLH and MAS share a
number of clinical and laboratory features. The most
significant differences are due to the inflammatory back-
ground of MAS: particularly platelet counts, as well as
fibrinogen levels, are usually higher in MAS compared
to pHLH. Primary HLH is caused by mutation in genes
that code for proteins that are involved in “perforin-me-
diated” cytolytic function. They are either proteins such
as perforin, directly involved in cytotoxicity, or proteins
involved in vesicle transport and fusion with the plasma
membrane.
There are several conditions associated with secondary
or acquired or reactive HLH. Although definitive epide-
miologic data are lacking, sHLH appear to be much
more frequent than pHLH. Among infection associated
HLH, Epstein Barr Virus is certainly the most common
trigger [2]. Additional typical triggers include other
Herpes viruses, Leishmania and H1N1 influenz [3–5].
There are a number of cases associated with lymphoma
and leukaemia, most frequently T cell receptor gamma-
delta bearing T cell lymphomas. These appear to be
rare in children, but this occurrence is rather frequent
in adults [6]. HLH can also be associated to an under-
lying rheumatic disease with sJIA being by far the most
frequent one. This form of sHLH is what paediatric
rheumatologist call MAS or rheuma-HLH. There is a
significant number of cases in which an apparent
underlying disease or an apparent underlying infection
cannot be found [7].
Genetics of MAS: contribution to defective cytotoxicity
As mentioned above, in pHLH, all causative genes code
for proteins involved in the cytotoxic pathway, in which
cytolytic granules are transported to and fused with the
cell membrane, and eventually pore-forming proteins,
such as perforin, are secreted in these immunological
synapses [8, 9]. If HLH is considered one clinical syn-
drome is conceivable that some of the pathogenic
mechanisms of pHLH may be involved in other forms
of HLH. See Appendix 2: Case 2 for potential impact of
heterozygosity for mutations of pHLH genes on devel-
opment of clinical overt disease and of a defective cyto-
toxicity [10].
One may also expect that a significant role for genetics
may impact on the recurrence of the disease. Indeed,
recurrent MAS in patients with sJIA is a well-known
phenomenon. However, information on the frequency of
recurrences is lacking from the large series reported in
recent papers [1, 11–14].
Kaufman et al. performed whole exome sequencing in
14 MAS cases on sJIA and found that 5 out of 14
patients (36%) were heterozygous for at least one muta-
tion of the known genes related to pHLH. In addition,
they found that 22 rare variants occurred in at least two
patients. Most of these variants code for proteins in-
volved in microtubule organization and vesicle transport
[11]. This suggested that cellular assembly and cytosche-
letal organization may be involved in the potential defect
in cellular cytotoxicity of these patients. A number of
other studies have previously looked at the frequency of
variants in the genes causing pHLH and overall they all
found a number of patients carrying either hypomorphic
variants or pathogenic mutations in heterozygosity in
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both UNC13d [15] and PRF1 [13]. In the context of the
Italian National Registry of familial HLH we performed
mutation analysis of genes involved in pHLH in 31 pa-
tients with sJIA and MAS. The analysis included PRF1,
UNC13d, STX11, STXBP2and RAB27a, and identified
monoallelic mutations in 11 of the 31 patients (35.5%).
Three out of 31 patients (9.7%) carried a mutation in 2
genes. Interestingly, it has been recently reported that
mice carrying heterozygous mutation in more than one
gene involved in pHLH carry a significant higher risk to
develop HLH following viral infection [16]. Overall, clin-
ical and laboratory feature of MAS in patients carrying
the mutations were not different from those of patients
who do not carry the mutation. However, recurrences of
MAS seem to be more frequent in patients who carry
the mutations (mutated 27% versus non-mutated 10%).
In our series of patients one patient died because of
MAS and she was heterozygous for a known pathogenic
PRF1 mutation (N252S) [17]. Altogether these observa-
tions, far from being conclusive, point to the presence of
a genetic contribution to MAS similar to that of pHLH.
All together these observations suggest that events re-
lated to the pathogenesis of pHLH are relevant in sHLH
in general, and in MAS in particular: a) accumulation of
partial genetic defect in one, or more than one, of the
known pHLH related gene b) the possible dominant
negative effects of some heterozygous variants [10, 18].
Defective cytotoxicity may impair clearance of infected
cells, and/or prolong lymphocyte-APC interactions, both
events leading to increased pro-inflammatory cytokine
production (e.g. IFNγ) by T lymphocytes [10, 19].
Different contributors to the development of a unique
clinical syndrome
In pHLH the contribution of genetics is so strong that,
even in the absence of any demonstrable trigger, genetically
caused immune abnormalities are sufficient to drive the
individual in full blown clinical HLH. In HLH secondary to
infection, in some instances, the strength of the infectious
agent is sufficient to cause HLH. Most of the patients who
died of H1N1 or H5N1 died with HLH [20]. There are
other agents that cause HLH rather often, as mentioned
above. In these instances, there must be a contribution
from the infectious agent, or more precisely from the
response elicited by a given infectious agent. In this re-
spect, it is interesting to note that gene expression profiles
of peripheral blood mononuclear cells from patients with
symptomatic mononucleosis show evident similarities
with gene expression profiles of patients with HLH or
MAS [21]. However, there must be also a contribution
from the genetic background. Schulert et al. found rare
variants in pHLH related genes in 5 out 14 cases of fatal
H1N1 influenza infection, all of whom had evidence of
hemophagocytosis. Five patients were heterozygous
for LYST mutation, two of them carried also a PRF1
mutation [22].
In MAS, the HLH clinical syndrome develops on the
background of a highly inflammatory disease such as
sJIA. Also in sJIA an infectious trigger appears to play a
role. Several MAS appears to be triggered by acute infec-
tions in patients with active sJIA. In a recent large multi-
national survey, this occurrence was documented in
approximately 1/3 of the cases [1]. In MAS, it is obvious
that an additional contribution must be provided by the
inflammatory status of the patient; indeed, the majority
of the MAS episodes occurs during active disease phases
or at disease onset.
Contribution of active inflammation to the development
of MAS
We generated a model of MAS using the interleukin-6
(IL-6) transgenic mouse (IL-6TG). In these mice, adminis-
tration of Toll-like receptor (TLR) ligands, including
lipopolysaccharides (LPS) and poly(I:C), induces the
development of MAS by mimicking an acute infection
on a background of high levels of IL-6 [23]. This
experimental approach recapitulates what occurs in
patients with systemic JIA: an infection triggers MAS
on a background of active disease, which is indeed
characterized by high levels of IL-6.
Compared to wild type mice, LPS-challenged IL-6
transgenic mice display an increased fatality rate and
show hematologic and biochemical features typically
present in MAS patients, including lower neutrophils
and platelet count, higher levels of ferritin and LDH, as
well as a cytokine storm.
When we looked at the stimulatory effect of IL-6, we
showed that, in vitro, prolonged exposure of human
macrophages to IL-6 leads to increased production of
cytokines and chemokines, including Tumor Necrosis
Factor-α (TNF-α) and (C-X-C Motif) Ligand 8 (CXCL-8),
both at a basal level and upon stimulation with TLR
ligands, suggesting a role for IL-6 in amplifying the
inflammatory response [24]. In addition, we demonstrated
that IL-6 amplifies TLR-induced inflammatory response
also in cells originating from inflammatory site, such as
synovial fluid mononuclear cells and fibroblast-like syno-
viocytes isolated from arthritides patients. Indeed, treat-
ments of these cells with IL-6 increased basal production
of CXCL8, C-C motif chemokine ligand 2 (CCL2) and
Interleukin-1β (IL-1β) following poly(I:C) and muramyl
dipeptide stimulation [24].
The other major feature of MAS in the context of sJIA
is the transitory defect in cellular cytotoxic function.
Grom et al. demonstrated that most of the sJIA patients
have profoundly decreased Natural Killer (NK) cell activity
[25]. The reduced NK cytotoxic activity observed was
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associated, in some patients, to a decreased perforin ex-
pression on NK cells and, in other patients, to a decreased
perforin expression on T-cells. However, overall, the great
majority of patients display a NK cytotoxic activity defect.
Consistently, we found that NK activity was impaired
also in the murine model of MAS, the IL-6TG. Indeed, IL-
6TG mice challenged with poly(I:C), a substitute for viral
dsRNA, display a significant decrease in NK cell cytotox-
icity, associated to lower expression levels of perforin and
granzyme B, in the absence of altered granule exocytosis
[26]. An example of IL-6 leading to decreased cytolytic
activity of lymphocytes on top of an underlying genetic
defect has been shown [10]. Similarly, in vitro experiments
revealed that exposure of human PBMCs to high levels of
IL-6, such as those typically present in sJIA, inhibits NK
cell cytotoxicity by down-regulating the expression of per-
forin and granzyme B. Altogether, this evidence suggests
that high circulating levels of IL-6 in JIA patients, besides
their role in increasing macrophage activation and TLR
response, play a major role in inducing a transitory defect
in cytotoxicity on top of a subclinical genetic defect.
In addition to IL-6, other inflammatory cytokines may
play a role in predisposition to MAS. Indeed, even in
patients treated with tocilizumab, in which IL-6 was fully
neutralized, MAS may occur [27]. One of the potential
candidates is IL-1β. There is a number of observations
pointing to the efficacy of high dose of anakinra in at
least some patients with MAS [28, 29]. On the other
hand, there is a number of studies describing patients
who developed clinically overt MAS while being treated
with both IL-1 blockers anakinra and canakinumab
[30–32]. In apparent contrast, in criopyrinopathies,
which are the purely IL-1β mediated, cases of MAS are
not described. Overall, these data would suggest that
neither IL-6 nor IL-1β alone may be the major contribu-
tors to the predisposition to MAS.
Increasing number of evidence suggests that interleukin-
18 (IL-18) might be another relevant mediator in sJIA. In a
study performed in Japan, the subset of sJIA patients char-
acterized by high levels of IL-18 (and conversely low levels
of IL-6) had a higher frequency of MAS episodes [12].
These data need to be confirmed in a Western population.
Albeit in a small number of patients, data from Put et al.
are consistent with this observation: in sJIA patients high
IL-18 levels do not markedly increase during active MAS,
pointing to IL-18 being a predisposing cytokine [33]. The
mechanisms behind the predisposing effect of IL-18 are
not clear yet. It is well know that IL-18 affects NK cell
activity, but preliminary evidence suggests that it may also
regulate macrophage responses [34].
Contribution of genetics to hyperinflammation
In addition to the known role of genetics of cytotoxicity
genes in HLH, recent evidence in animals and humans
suggest that genetics may also play a major role in
contributing to hyperinflammation and particularly to
macrophages hyper-responses. Indeed, data in the
animals clearly support this hypothesis. The most stud-
ied model of genetically driven HLH are perforin
knock-out mice which, upon LCMV infection, develop
full blown HLH and die [35]. When UNC13d deficient
mice are crossed with mice deficient for MYD88, which
is a central element in TLR intracellular signalling, the
animals are protected from disease development,
demonstrating that, at least in animals, TLR signalling
and macrophage responses are crucial [36]. Indirect
evidence in humans has been provided by a study
suggesting that a polymorphism in IRF5, a transducer
of intracellular TLR, is associated with the risk of MAS
in patients with sJIA [37]. In addition and much more
importantly, direct evidence in humans is provided by
the recent observation that gain of function mutations
of NLRC4, an inflammasome sensor, cause a disease
characterized by recurrent or dramatic HLH. This
observation demonstrates in humans that genetically
induced abnormalities in autoinflammation cause HLH.
The disease, still described in very few patients appear
to be characterized by early onset of fever, skin rash,
severe gastro-intestinal involvement, splenomegaly and
recurrent, severe MAS/HLH [38, 39]. Immunological
studies revealed that the most striking abnormality is
represented by surprisingly high levels of IL-18 pointing
to the fact that the NLRC4 protein is particularly
important in regulating IL-18 production and further
supporting the role of IL-18 as a predisposing factor to
HLH/MAS [38].
Different contributors and one pathogenic mediator?
It is reasonable to hypothesize that several factors, act-
ing at different steps, contribute to the development of
MAS and sHLH. A multilayer model of pathogenic
events leading to the development of MAS has been
proposed, including genetics, inflammatory activity and
infection, contributing to reaching a threshold of
activation that results in overt MAS [40]. In perforin
knock-out mice infected with LCMV, the most used
mouse model of primary HLH, neutralization of a
number of cytokines does not produce any relevant
clinical effect. However, neutralization of IFNγ leads to
protection from disease and to survival of the animals
[35]. Based on a number of experiments both in mice
and on human cells, it has been hypothesized that
mutations of genes impacting on cytotoxic activity
generate an inability of cytotoxic T cells to lyse the
target cells. This defect leads to prolonged hyperactiva-
tion of T cells with hyperproduction of IFNγ [10, 19].
High levels of IFNγ leads to activation of macrophages,
as a compensatory mechanism aimed at phagocytosis of
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the infected cells. Indeed, these patients do not suc-
cumb from overwhelming infections. These activated
macrophages produce very large amounts of inflamma-
tory cytokines and generate a cytokine storm, which is
the driver of the clinical and laboratory features of
HLH and eventually leads the host to death, if left
untreated.
Translating from pHLH to MAS and based on the
similarities in clinical and laboratory features as well as
in genetic contribution, we have recently investigated
whether IFNγ could potentially be involved also in
MAS. IFNγ levels were found to be higher in patients
with active MAS at sampling compared to patients
with active sJIA without MAS at sampling [41]. Using
the above mentioned mouse model of MAS in IL-6
transgenic mice we have also found that neutralization
of IFNγ improved survival and reverted biochemical
abnormalities (Prencipe G. 2016 submitted). Interest-
ingly, in patients with MAS a marked increase in
CXCL9 levels was also found. CXCL9 is known to be
specifically induced by IFNγ [42]. Indeed in patients
with active MAS levels of IFNγ and CXCL9 were
strictly related to laboratory features of MAS, including
ferritin levels, white blood cell and platelet counts, and
LDH [41]. These correlations were not present in pa-
tients with active sJIA without MAS. These data sug-
gest that during MAS, but not during active sJIA, there
is a specific activation of IFNγ and of the IFNγ path-
way. Noteworthy in the NLRC4 patient, reported by
Canna et al., one of the cytokines that increases signifi-
cantly during active HLH episodes is indeed CXCL9
[38]. We also found high levels of CXCL9 in a patient
with NLRC4 induced disease (unpublished). Observa-
tions in MAS and in NLRC4-induced disease show that
hyperinflammation induced by dysregulated inflamma-
tory responses may directly cause overproduction of
IFNγ.
Conclusion
All together these observations are consistent with the
hypothesis that HLH may be one clinical syndrome
maintained by one effector mechanism, which involves
increased macrophage activation and increased T-cells
activation. In this loop, IFNγ seems to play a major role.
In classical pHLH, genetic mutations and the conse-
quent defect in cytotoxic pathways are sufficient to drive
a patient above the threshold eliciting this vicious loop.
NLRC4-induced disease provides proof of concept that
genetic predisposition to inflammasome hyper-response
alone can drive patients directly into the same vicious
loop. In patients with MAS an additive/synergist role is
played by several contributors, including infectious trig-
gers, genetics, of both cytotoxicity and inflammatory
response, and inflammatory activity of the underlying
rheumatic disease. Recently generated evidence points to
IFNγ as the major mediator also of HLH secondary to
infections [43, 44], as well as of MAS. These findings
may have significant translational value. A monoclonal
antibody to IFNγ is in clinical trial in primary HLH with
initial satisfactory response [45] and a trial in MAS is
being planned.
Appendix 1: Case 1
Case 1
An 8 years old Caucasian boy with sJIA onset one year
before, suddenly developed persistent fever, generalised
seizures, hypotension, purpura and splenomegaly.
Laboratory picture was completely different if compared
to his laboratory at sJIA onset. Blood count showed
leukopenia with neutrophenia and anemia. Erithrocyte
sedimentation rate (ESR) was relatively low, however
CRP was high as it was. Fibrinogen was low because of
intravascular activation of the coagulation, d-dimers
were high. He presented also liver involvement with
some degree of liver insufficiency. The most striking
feature was hyperferritinimia, which was markedly
higher compared to sJIA presentation (Table 2). This
case represents a typical picture of MAS complicating
sJIA. Changes in laboratory features are the hallmark
and these have been recently mathematically character-
ized in multination effort [1]. However, MAS may repre-
sents a significant challenge when occurring at sJIA
onset.
Table 2 Patient’s laboratory features
Laboratory Features sJIA presentation MAS presentation
White blood cells, x109/L 15.04 3.02
Neutrophils % 86% 19%
Haemoglobin, g/dL 9.08 7.09
Platelet, x109/L 640 125
Ferritin, ng/mL 880 11345
ESR, mm/h 98 32
CRP, mg/dL 13.08 19.07
Fibrinogen, mg/dL 560 88
D-dimers, ng/mL <10 >40
Sodium, mEq/L 136 129
ALT, U/L 23 180
AST, U/L 18 145
LDH, U/L 380 1910
Bilirubin, mg/dL 0.06 2.06
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; ALT, alanine
aminotransferase; AST, aspartate aminotransferase; LDH,
lactate dehydrogenase
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Appendix 2: Case 2
Case 2
A 15 years-old, Caucasian male presented with persist-
ent fever since 4 weeks, diarrhoea vomiting, skin rash,
hepatosplenomegaly, and elbows arthritis. Blood tests
showed high ferritin (5896 ng/ml), liver inflammation
(AST 224 IU/l, ALT 635 IU/l, LDH 676 IU/l), and intra-
vascular activation of coagulation with high d-dimers
(2.26 μg/ml), and a bone marrow biopsy showed hemo-
phagocytosis. He was treated with glucocorticoids, cyclo-
sporine A and cyclophosphamide with good response.
Three years later, he presented again with persistent
fever, skin rash, diffuse arthralgia, and myalgia. He re-
ferred to the malaise and arthralgia as being the “same
disease” as the one 3 years before. As soon as ferritin
started to rise significantly (5481 ng/ml), dexamethasone
and cyclosporine A were started with a prompt response.
He was found to carry a single copy heterozygous mis-
sense mutation in RAB27a. This same mutation was
found in his father, who was apparently healthy, but who
had a baseline moderately high serum ferritin level
(800 ng/ml). Functional tests showed a marginal defect
in CD107a degranulation in the patient and his healthy
father [10]. Indeed experiments with this very mutation
have shown an impact on cytotoxic function as well as
on the duration of the immune synapses [10]. This pa-
tient appears to have had two episodes of HLH, which
cannot be strictly defined as primary or genetic HLH; it
is however, tempting to speculate that carriage of this
mutation plays an important role in the two recurrences
of secondary HLH.
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